

MosaiQ® Scientific Communications Autoimmunity



The MosaiQ® solution is designed to empower laboratories to deliver diagnostic confidence to clinicians. This material is intended to provide an overview of the scientific communications of the MosaiQ® Autoimmune Program.

MosaiQ offers comprehensive panels with the potential to advance the diagnosis of autoimmune diseases by accelerating laboratory workflows and time to result. Designed to aid clinicians to make better informed, early and personalized clinical decisions.

Visit www.alivedx.com or scan the QR code for more information and to schedule a meeting with us.



Scan the QR codes to go directly to the references

MosaiQ®
Aiplex CTDplus



Click to open

MosaiQ® AiPlex™ CTDplus prototype showed substantial agreement with the standard of care in a French major reference center.¹

MosaiQ® AiPlex-CTDplus prototype demonstrated substantial agreement with CE-marked devices for the detection of the fifteen evaluated autoantibodies. Formal clinical and analytical performance evaluation studies will demonstrate the performance characteristics of the final product design. This solution has the potential to advance the diagnosis of several systemic autoimmune rheumatic diseases by accelerating laboratory workflow and time to results, empowering clinicians to make better informed, early and personalized clinical decisions.

MosaiQ®
Aiplex CTD



Click to open

MosaiQ® AiPlex CTD showed substantial agreement with the compared CE-marked devices.²

In this sample cohort from a Spanish reference center, MosaiQ® AiPlex CTD showed high concordance with CE-marked devices for the detection of the eleven studied autoantibodies, which is in line with previous observations in a larger cohort using FIDIS and other CE-marked devices.

Click the QR-codes to go directly to the references

MosaiQ® Aiplex CTDplus



[Click to open](#)

MosaiQ® AiPlex CTDplus prototype's preliminary results showed substantial agreement with the compared CE-marked devices.³

MosaiQ® AiPlex CTDplus prototype's preliminary results showed substantial agreement with the compared CE-marked devices. Further studies with the final product design will allow for expanded performance assessment of the device. This fully automated multiplexed platform could help optimize CTD evaluation by simplifying complex testing pathways and analyzing larger number of samples per day.

MosaiQ® Aiplex CTD



[Click to open](#)

MosaiQ® AiPlex CTD showed significant agreement with the compared CE-marked devices.⁴

MosaiQ® AiPlex CTD showed high concordance with compared CE-marked devices, for the automated simultaneous qualitative detection of the eleven autoantibodies included in the assay. Future product developments will include the addition of other autoantibodies to the microarray and semi-quantification.

MosaiQ® Aiplex CTD



[Click to open](#)

MosaiQ® AiPlex CTD preliminary results showed substantial agreement with the compared CE-marked devices.⁵

Solid preliminary performance results support the MosaiQ® AiPlex CTD microarray. Larger studies to further evaluate the performance of the investigational device are ongoing. The MosaiQ® System has the potential to advance CTD testing by increasing laboratory efficiency and productivity by automatically analyzing multiple autoantibodies simultaneously and processing larger number of samples per day.

MosaiQ® Aiplex CENP-B



[Click to open](#)

MosaiQ® AiPlex CENP-B showed notable agreement with the compared CE-marked devices.⁶

MosaiQ® CENP-B microarray shows high concordance with other CE-marked assays for detecting autoantibodies against CENP-B, with demonstrated reproducibility and repeatability. MosaiQ® System has the potential to improve laboratory efficiency and productivity, with the ability to multiplex the detection of various autoantibodies on a single microarray and a capacity to automatically process samples, delivering a large number of results per day.

MosaiQ® Aiplex CENP-B



[Click to open](#)

MosaiQ® AiPlex CENP-B prototype's preliminary results showed substantial agreement with the compared CE-marked devices.⁷

MosaiQ® CENP-B microarray provides a high level of clinical concordance with other CE-marked assays for detecting anti-CENP-B autoantibodies (ACA-B). The MosaiQ® System has the potential to advance autoimmune disease testing by increasing laboratory efficiency and productivity, with the ability to multiplex the detection of various autoantibodies on a single microarray, and a capacity to automatically process large number of samples per day.

1. Gomez G et al. B-073 Poster Planner ADLM 2024

2. Gomez G et al. B-072 Poster Planner ADLM 2024

3. Bijlsma D et al. Clinica Chimica Acta. 2024;558(Suppl 1):118502

4. Ghillani-Dalbin P et al. Clinica Chimica Acta 2024;558(Suppl 1):118524

5. Daphne Bijlsma et al. Arthritis & Rheumatology, 2023;75(S9):1148

6. Ghillani-Dalbin P. Immunochem Immunopathol, 2023; 9:6

7. Daubrosse C et al. Clinical Chemistry. 2023;69(Suppl 1):hvad097.397.

© AliveDx Suisse SA, 2024. AliveDx, the AliveDx logo, AiPlex and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories.

GFD#:0.0122.v1